Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_00318 |
| Species: | Homo sapiens |
| Position : | chr2:176265000-176270000 |
| Year: | 2022 |
| Title: | EWS::FLI1 and HOXD13 control tumor cell plasticity in Ewing sarcoma |
| Genome Build: | hg19 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| Disease Name: | -- |
| PMID: | 35653119 |
| MONDO: | |
| Tissue: | Blood |
| Tissue Ontology ID: | UBERON:0000178 |
| Cell Source: | K562 erythroleukemia cells |
| CVCL ID: | CVCL_0004 |
| Cell Type: | chronic myeloid leukemia cell |
| Cell Ontology ID: | CL:0001054 |
| Experiment Type: | Enhancer activity assay, TF binding assay, Chromatin interaction assay, Functional perturbation assay |
| High Throughput Method: | ChIP-seq, RNA-seq, Hi-C |
| Low Throughput Method: | ChIP-RT-qPCR, CRISPR Knockout, CRISPRi, RT-RT-qPCR |
| Target gene : | HOXD13 |
| TF name : |
| Regulatory State : | Active |
| GeneName | Pathway Name | Source | Gene Number |
|---|
| Enhancer ID | Position | Tissue | Cell | Disease |
|---|---|---|---|---|
| E_00317 | chr2:176265000-176270000 | Heart | cardiomyocyte | -- |